Ma waho aʻe o ka LC-MS Hoʻokahi-Dimensional: He aha ka Q-2DMS i hiki ke hoʻololi i ka peptide characterization

Pane wikiwiki

A main peak passes HPLC area-percent release while a closely related species hides inside it. That failure mode is the reason Q-2DMS in peptide characterizatio…

Kūʻai Kūʻai Kūʻai Kūʻai Kūʻai Nā Peptides pololei ʻEkolu mau hana poho e hana ma ke kaʻina, a ʻo ka mua wale nō i ʻike ʻia ma kahi chromatogram. Hoʻokomo ʻo Chromatographic co-elution i ʻelua ʻano i loko o ka puka aniani mālama like; ka kānana precursor pili i ka ʻikepili a laila koho i kekahi o ia mau mea; hāʻule nā ​​ʻano haʻahaʻa haʻahaʻa i hiki ʻole i ka paepae ikaika. ʻO ka hopena spectral he spectrum chimeric, ʻaʻole hiki ke hāʻawi ʻia nā ʻāpana ʻāpana i kahi precursor hoʻokahi.

Ma waho aʻe o ka LC-MS Hoʻokahi-Dimensional: He aha ka Q-2DMS i hiki ke hoʻololi i ka peptide characterization

Ana ʻia ka nui o ia hopena. E hana i ka helu ʻana i nā kikoʻī chimeric MS/MS i nā hōʻike e pili ana i ka ʻikepili i hiki ke hōʻike i nā chimeras 30 i 50% o ka huina MS/MS spectra i ohiia, a me ka haiki 2 m/z pukaaniani kaawale, 39% ʻO nā kikoʻī mai ka tryptic HeLa digests he chimeric (pepa chimeric spectra method e hai ana ia Houel et al. 2010 a me Dorfer et al. 2018). Hoʻomaopopo ke kumu hoʻokahi i ka hoʻohaʻahaʻa ʻana o ka chimerism i nā helu huli mai MASCOT a me SEQUEST a hoʻoulu i ka hoʻoemi ratio i ka helu isobaric-tag..

ʻO ka helu ma lalo o ka laʻana mai ka mea like 2011 Nūpepa no ka Proteome Research ke aʻo ʻana i ka hiki ke komo i ka DDA: he helu MS/MS scan o 25 i kēlā me kēia kekona i makemake ʻia e huli i nā hiʻohiʻona peptide āpau i ʻike ʻia, e hāʻule ana i lalo 17 i kēlā me kēia kekona no ka nui o nā peptides, a me nā hiʻohiʻona he nui i koi ʻia i nā manawa injection MS/MS ʻoi aku ka lōʻihi ma mua o 250 ms (ʻo Michalski, Cox a me Mann, 2011). ʻIke nā mea kākau i ka hoʻokaʻawale ion precursor, ʻaʻole scan wikiwiki, e like me ka palena nui loa.

ʻO ka hana "no laila he aha" ʻo ia ka hāʻule ʻole. Hiki i ke ala ke hele i ka ho'āʻo hoʻokuʻu ʻana ma ka pākēneka ʻāpana aʻo kahi ʻano co-eluting e hāʻawi i nā ʻāpana i hoʻohālikelike ʻia i ka spectrum o ka piko nui., ʻaʻohe mea i loko o ka chromatogram e hae. ʻO ia ka ʻāpana kikoʻī i hoʻolālā ʻia e pani ʻia kahi ala ʻelua-dimensional mass spectrometry peptide analysis approach, no ka mea, wehe ia i ke kaʻina koho precursor ma mua o ka hoʻonui ʻana.

He aha ka Q-2DMS a pehea ka ʻokoʻa mai ka 2D-LC?

ʻO Q-2DMS ka 2DMS i hana ʻia ma kahi mea hana quadrupole time-of-flight, me ka quadrupole i hana ʻia ma ke ʻano he pahele ion ma mua o ke kānana lehulehu. ʻO ka hoʻolaha ʻana o ke Kulanui o Warwick i ka hōʻike mua Q-2DMS benchtop e wehewehe ana i ka hana a Warwick a spin-out Verdel Instruments ma ke ʻano he hōʻike mua o 2DMS ma kahi mea hana Q-TOF i kūʻai ʻia me ka hoʻohana ʻana i kahi pahu hoʻonui. (Kulanui o Warwick, 2026).

Pono ka terminology i ka poli ma mua o ke kamaʻilio ʻana o ka mea kūʻai aku, no ka mea, hoʻopili nā hualoaʻa i nā ʻenehana ʻelua. 2Mālama ʻo DMS i ka precursor a me ka ʻāpana m/z ma ke ʻano he ʻelua hoʻonohonoho a hoʻoponopono iā lākou; 2D-LC, inā ʻoki puʻuwai a i ʻole LC×LC piha, He ʻenehana chromatographic e hoʻomaikaʻi i ka hoʻokaʻawale ʻana akā ʻaʻole hoʻopili i kahi ʻāpana i kona mua.. Hōʻike ka loiloi 2DMS i ka ʻokoʻa mai ka ʻaoʻao ʻē aʻe: 2Hāʻawi ʻo D MS i kahi ala e hoʻoponopono ai i ka precursor a me nā ʻāpana ʻāpana me ka ʻole e koi i ka hoʻokaʻawale mua, ʻo ia ka mea e hiki ai ke ʻike i nā ʻano ʻāpana o nā pūhui āpau i kahi laʻana paʻakikī (ʻElua-dimensional mass spectrometry: nā manaʻo hou no ka tandem mass spectrometry, 2019).

ʻO ka mīkini, e like me ka mea i ho'ākāka 'ia ma ke kula Q-2DMS mua ma Kemika Analytical, holo i na anuu eha. Hoʻopaʻa ʻia nā Ion i ka quadrupole ma ka hoʻonohonoho ʻana i nā volta lens 25 V ma luna o ke koʻokoʻo pili, me kēlā me kēia pulse SWIM mau loa 20 ms a me ka hauʻoli nui loa ma waena 5 a 13 ms; he kaina o 1024 Hāʻawi nā pulse SWIM i ka loaʻa ʻana o 17 mau minuke (Wright et al., Kemika Analytical, 2026). Loaʻa ka ʻāpana i ka wā o ka modulation, na CID in-trap a i ole 213 nm UVPD i hāʻawi ʻia ma o ka puʻu pusher, a laila ana ka TOF i ka huahana-ion m/z. Hoʻihoʻi hou ka loiloi Fourier o ka moʻo modulation i ka axis precursor.

ʻAʻole hou ka manaʻo. Hōʻike ka loiloi 2DMS i ka hana i paʻi ʻia ma 1987 ka mea i hana i ʻelua mau ʻāpana nui ma ka hoʻopili ʻana i ka precursor m/z a hoʻopili iā ia me ka ʻāpana m/z i loko o kahi kelepona FT-ICR. (ʻElua-dimensional mass spectrometry: nā manaʻo hou no ka tandem mass spectrometry, 2019). He aha ka mea hou ma ka 2026 ʻO ka hana ka papa lako, ʻaʻole ke kumu.

2ʻAʻole ʻo DMS he 2D-LC. Hoʻopaʻa kekahi i ka correlation precursor-fragment ma ke ʻano he ana nuipa lua; ʻo ka mea ʻē aʻe e hoʻomaikaʻi i ka hoʻokaʻawale ʻana ma mua o kahi ana nui.

Pehea ka ʻokoʻa ʻana o Q-2DMS mai ka 2DMS-cell-ICR?

ʻO ka ʻokoʻa ka pale ʻana i nā lako, ʻaʻole ka manaʻo. Ke holo nei ʻo Q-2DMS ma luna o kahi pā hale kūʻai Q-TOF me kahi pahu hoʻonui, ʻoiai ʻo 2DMS e pili ana i ka ICR e koi i kahi mea hana FT-ICR loea kiʻekiʻe, ka mea i wehewehe ʻia e ka Warwick hoʻolaha e like me ke kumukūʻai mua wale nō i nā kikowaena kālā maikaʻi loa (Kulanui o Warwick, 2026).

Noho nā helu hana i nā pae like ʻole, a he pono e heluhelu ʻia lākou me ka ʻole o ka hoʻohālikelike pololei ʻana. ʻO ka loiloi 2DMS e uhi ana i nā hōʻike hana FT-ICR e hoʻoholo ana i ka mana ma m/z 400 ʻoi aku ka maʻalahi 230,000 ma kahi 1 s kuewa, me ka nui o ka pololei ma mua o 1 ppm no kahi ion ma m/z 400 ma kahi 12 T kahua, e pili ana iā Nikolaev et al. 2012 (ʻElua-dimensional mass spectrometry: nā manaʻo hou no ka tandem mass spectrometry, 2019). ʻO ke aʻo mua Q-2DMS ma Kemika Analytical hōʻike i kahi mana hoʻonā precursor-axis o M/ΔM ≈ 100 mai ka nānā 'ana i ka laula peak o ka axis precursor (Wright et al., 2026).

ʻOkoʻa ke ʻano o ke koʻi huahana mai ka axis precursor ma ka mea hana Q-TOF. Ka like pepa hōʻike huahana-axis nuipaʻa pololei o 2.5 ppm a me ka laula peak o 0.01 m/z ka laula piha ma ka hapalua o ka nui, no ka mea, ua paʻa ka hana a ka mea ananala TOF ma ia ana (Wright et al., 2026). No laila, ʻo ka helu precursor-axis haʻahaʻa he waiwai ia o ka hoʻolālā modulation a me ka decoding, aole o ka mea ike.

Pono e hoʻopaʻapaʻa ʻia kekahi paio ʻike ʻia no ka mea he mea hana ia ma mua o ka ʻoiaʻiʻo. Hōʻike ka loiloi 2DMS ʻaʻole kūpono ʻo CAD me 2D MS no ka mea ʻo ka loaʻa ʻana o ke kinoea i loko o ka cell ICR e hoʻopau i ka hui pū ʻana o ka ion., ʻo ia ke kumu i hoʻohana nui ʻia ai ka IRMPD a me ECD (ʻElua-dimensional mass spectrometry: nā manaʻo hou no ka tandem mass spectrometry, 2019). Hana ka hana Q-TOF i ka CID i loko o kahi pahele quadrupole a hōʻike i ka spectra 2D CID o kahi hui peptide. (Wright et al., 2026). Hōʻike ʻia ka palena o ka loiloi no ka cell ICR, a ʻaʻohe kumu e ʻōlelo inā e hoʻololi ʻia i kahi pahele quadrupole.

ʻAʻohe kumu e kākoʻo i ka hoʻohālikelike hoʻonā-mana ma waena o nā paepae ʻelua ma mua o kēia mau helu. Ka mana hoʻonā 2D o ka loiloi, i wehewehe ʻia ma mua o 10⁷, ʻAʻohe ona hoa pili i nā huaʻōlelo Q-TOF, no laila ʻaʻole hiki ke hoʻohana ʻia e hoʻonohonoho i nā paepae.

He aha ka 'ikepili spectral hiki ke hoʻohana i ka ʻumi mau manawa' e hoʻomaha maoli ai?

Hiki ke kiʻi pāʻumi i hoʻokahi kumu i luna. Ua ʻōlelo ka hoʻolaha o ke Kulanui o Warwick, ua mālama ʻo Q-2DMS i ka ʻike heʻumi i ka ʻike kikoʻī i hoʻohana ʻia i ka wā e nānā ana i nā pūhui pili pili a kokoke-isobaric. (Kulanui o Warwick, 2026), a ʻo kēlā me kēia mea nūhou i lalo e hoʻokaʻawale i kēlā pepa hoʻokahi ma mua o ka hana hou ʻana ma ke kaʻawale.

ʻOi aku ka kikoʻī o nā helu ponoʻī o ka pepa ma mua o ka mea hoʻonui. ʻO ke aʻo mua Q-2DMS ma Kemika Analytical hōʻike i nā kiʻekiʻe huahana-ion he nui ma Q-2DMS e pili ana i kahi 100 Hiki ke hoʻohana ʻia nā kiʻekiʻe o nā huahana-ion i ka kikoʻī MS/MS maʻamau, no kahi hui ʻehā-peptide o ka polymyxin B1, melittin, bacitracin A a me ka mea P (Wright et al., 2026). Ua hoʻohana ka hoʻokolohua i ka infusion pololei, CID a me 20 eV i loko o ka pahele a me ka beam CID, a me UVPD ma 213 nm me ke kukui CID i hoemiia ma 8 eV, me ka CID hoʻopaʻa ʻana o 333 ng/mL no ka polymyxin a me ka mea P a me 667 ng/mL no ka bacitracin a me ka melittin, hoʻokiʻekiʻe ʻelima no UVPD (Wright et al., 2026).

Aia ka scope i ka hanu like me ka helu. He hana hōʻoiaʻiʻo kēia ma kahi hoʻonohonoho peptide palena, loaʻa ma ka infusion pololei ma mua o ke ʻano chromatographic i hōʻoia ʻia, a ʻaʻole i ʻike ʻia kahi hana hoʻohua kūʻokoʻa. ʻAʻole i hoʻopaʻa ʻia ka huaʻōlelo hoʻopuka paʻi "a hiki i ka ʻumi" i kahi metric i wehewehe ʻia e pili ana i ka M/ΔM ≈ 100 precursor-axis resolving power or the 0.2 hōʻike ʻia ka ʻokoʻa maʻamau m/z ma ka pepa, no laila pono e mālama ʻia ka multiplier ma ke ʻano he poʻo ma mua o kahi kikoʻī.

ʻElemu koi

He aha ka mea mua Nā Peptides mokuʻāina kumu

palena palena

ʻOi aku ka ʻike spectral hiki ke hoʻohana

Ma kahi kokoke 1,000 product-ion peaks versus ma kahi o 100 ma MS/MS maʻamau

ʻEhā-peptide hui, pololei Kūʻai nui ʻia ʻo Peptide infusion, hoʻokahi hale hoʻokolohua

Mana hoʻonā precursor-axis

M/ΔM ≈ 100

Nānā S3 kiʻekiʻe-ākea

Hoʻokaʻawale pili pili mua

0.2 ʻokoʻa m/z i hoʻokaʻawale ʻia

Hoʻokaʻawale maʻamau 0.2 pale ka m/z i ka kaawale piha

Hana huahana-axis

2.5 ppm pono nuipa, 0.01 m/z laula piko

Hoʻopaʻa ʻia ka hana anana TOF ma kēia ana

ʻO kēia ʻatikala kahi loiloi hiki i ka hana hōʻoia-o-maʻamau i paʻi ʻia, ʻaʻole i hoʻohālikelike ʻia ke ʻano hoʻohālikelike, a ʻaʻole ʻōlelo ʻo ia i ke poʻo-a-poʻo quantitative benchmark.

ʻO nā peptide haumia a me nā hoʻololi e hiki ke hoʻoholo, a o ka mea hiki ole?

Hoʻopuka ʻo Q-2DMS i ka hihia isobaric a kokoke i ka isobaric ma o ka mālama ʻana i ka ʻike mua ma o ka hui pū ʻana., a ʻo ka palena hoʻokae i paʻi ʻia ʻo ia ka helu e hoʻolālā a puni. ʻO ke aʻo mua Q-2DMS ma Kemika Analytical hōʻike e ʻokoʻa nā precursors wale nō 0.2 Ua hoʻokae ʻia ka m/z, me ka hoʻohana ʻana i ka bacitracin [M+3H]3+ a me ka melittin [M+6H]6+ ma y ≈ m/z 475, me ka puunaue ana iloko 0.3 m/z o nā waiwai i manaʻo ʻia o m/z 475.1329 a me m/z 474.9236 (Wright et al., 2026).

ʻO ka pepa hoʻokahi i hōʻike maopopo i ka palena: ʻo ke kuhi maʻamau i nā hihia ʻelua 0.2 m/z, ʻaʻole e ʻae i ka hoʻokaʻawale piha ʻana o nā puʻunaue ʻelua, a ʻo ka walaʻau ma ka ʻaoʻao alapine ka hāʻawi mua ʻana i kēlā laula (Wright et al., 2026). ʻO ke ʻano hana e hiki ai i ka hoʻokae hapa ʻana, ʻo ia ka hoʻoili ʻia ʻana o ka pūlima modulation o kahi precursor e kāna huahana a hoʻololi ʻia e Fourier transform., no laila e hoʻopili ʻia nā ʻāpana i ko lākou precursor maoli ʻoiai ke hui pū ʻia nā precursors he nui (ʻElua-dimensional mass spectrometry: nā manaʻo hou no ka tandem mass spectrometry, 2019).

E hoʻokaʻawale i nā ʻano mea kokoke-isobaric mai nā isomers-nuipa nui. ʻO ka hoʻokaʻawale ʻana i ʻoi aku ka nui ma mua o ka ʻokoʻa maʻamau i hōʻike ʻia ʻaʻole ia e hōʻoia i ka hoʻonā kumu; mokuʻāina uku, hōʻailona-i ka walaʻau, He mea nui ka decoding a me ka peak shape. Pono nā isomers kikoʻī i ka ʻāpana diagnostic a i ʻole ka hoʻokaʻawale orthogonal i hōʻike ʻia no ka pālua..

Hoʻopuka pū ka pepa i kahi hoʻoponopono kūpono no ka hihia overlap. Kahi melittin [M+6H]6+ a me ka bacitracin [M+3H]3+ ʻāwili ma ka m/z 475, Hiki ke hoʻokaʻawale ʻia ka melittin me kāna [M+5H]5+ mua ma m/z 570, a laila hoʻopau ʻia kona mau ʻāpana mai ka moʻo ʻāwili, e ʻae i ka bacitracin e hoʻonohonoho ʻia (Wright et al., 2026). ʻokoʻa ka mokuʻāina uku, ʻaʻole hoʻoholo mana, hoʻoholo i kēlā pālua.

0.2 ʻO ka m/z kahi palena hoʻokae i paʻi ʻia i ana ʻia ma kahi hui ʻehā-peptide, ʻaʻole kahi kikoʻī.

E hoʻokaʻawale i nā huaʻōlelo hoʻokuʻu i ka wā e loiloi ana i kekahi o kēia. Maemae, ʻike ʻike, ʻupena maʻiʻo a me ka counterion, kūpaʻa, a ʻo ka hoʻāʻo ʻana he mau ʻano ʻokoʻa, a ʻo ke ala e hoʻomaikaʻi ai i ka hilinaʻi ʻike, ʻaʻole ia e hoʻokumu i ka maʻemaʻe a i ʻole ka ʻike.

I ka wā hea e pono ai nā ʻano orthogonal?

Pono nā ʻano hana Orthogonal ma nā wahi a pau i hāʻule ai kahi manaʻo hoʻoponopono a i ʻole kahi nīnau hoʻolālā ma waho o ka mea e hiki ai i ka correlation precursor-fragment ke pane.. ʻO ke alakaʻi ʻEulopa e pili ana i ka hoʻomohala ʻana a me ka hana ʻana i nā peptides synthetic e paipai i ʻelua mau ala orthogonal no ka ʻike ʻana i ka kikoʻī a me ka hoʻokuʻu., papa helu lehulehu, manawa paʻa pili, LC-MS, palapala palapala peptide, bioactivity, ka nānā ʻana i ka waikawa amino a me ka NMR i kūpono, a koi ʻia ka hui ʻana i koho ʻia me ka maopopo ʻole i ke kaʻina (ʻO ke alakaʻi a EMA i ka hoʻomohala ʻana a me ka hana ʻana i nā peptides synthetic).

Hoʻonohonoho ke alakaʻi like i ke ʻano haumia e pono e lawelawe ʻia e kekahi ala hou. Pono e hōʻike ʻia nā mea haumia pili i ka peptide ma luna 0.1%, i ʻike ʻia ma luna 0.5% a kūpono ma luna 1.0% ma lalo o ka Ph. Eur. monograph maʻamau i nā mea no ka hoʻohana lāʻau lapaʻau, a ma kahi e ʻike ʻia ai ka hui ʻana o nā haumia e like me ka piko hoʻokahi, ka 1.0% pili ka paepae hoʻonaʻauao ke ʻole ke ʻāpono ʻia (ʻO ke alakaʻi a EMA i ka hoʻomohala ʻana a me ka hana ʻana i nā peptides synthetic). Hoʻomaopopo pū ʻo ia i ka mana o nā diastereomers e koi i nā ʻano kikoʻī, ʻo ia ka māhele Q-2DMS ʻaʻole i kamaʻilio.

Ua haʻalele ka FDA i ka Mei 2021 synthetic-peptide ANDA alakaʻi i Iulai 2026. ʻAʻole i hoʻokumu ʻia nā paena mōʻaukala mai kēlā palapala i kahi palena peptide honua. E noi i ke alakaʻi kikoʻī huahana pili a me kona kūlana. E nana ʻO ka hōʻano hou o FDA.

No laila, ʻaʻole he nīnau hoʻololi ka Q-2DMS me LC-MS/MS. ʻO ke aʻo mua Q-2DMS ponoʻī e hilinaʻi ʻia i kahi ʻano haʻahaʻa-collision-energy a i ʻole laser-off 1D spectrum e hōʻike i nā precursors āpau me ka hoʻonā TOF piha a me ka pololei nui., a ua ʻōlelo ʻo nā mea mua ʻaʻole e hoʻokaʻawale piha ʻia i ka spectrum 2D ua maʻalahi ka hae. (Wright et al., 2026). Ke hana nei ke ana 1D i ka hiki ole ke ana 2D.

Ua mākaukau ʻo Q-2DMS no ka QC maʻamau i hōʻoia ʻia, a he aha ka mea a ka mea loiloi e noi ai?

ʻAʻole hōʻike ʻia ʻo Q-2DMS ma kekahi kumu i loaʻa ma ke ʻano he ala QC maʻamau i hōʻoia ʻia, a ʻo ke kumu hōʻike he haʻawina hōʻoia hoʻokahi. ʻO ka mea a ka mea loiloi e noi ai e wehewehe ʻia e ICH Q2(R2), ke alakaʻi no ka hōʻoia ʻana i nā kaʻina hana analytical, hāpai ʻia ma Step 4 ma 1 Nowemapa 2023, e hoʻohana ana i ka huaʻōlelo o nā hiʻohiʻona hana a papa inoa i ka kikoʻī a me ke koho, laula, pololei, pololei, palena ʻike, palena nui a me ka ikaika (I Q2(R2), 2023). Kūʻai nui ʻia nā Peptides Synthetic

Nīnau loiloi

ʻO nā mea i hōʻike ʻia i kēia manawa

He aha ka mea i nalowale

Ka kikoʻī a me ke koho

Hoʻokaʻawale hapa o nā mea mua 0.2 m/z kaawale; mālama ʻia ke ʻano isotope

Hōʻike ma waena o nā papa haumia, ʻaʻole hoʻokahi hui ʻehā-peptide

Ka palena a me ka nui

Hōʻike ka ikaika kiʻekiʻe ma ka laina autocorrelation i ka nui a me ka maikaʻi o ka ʻāpana

ʻAʻohe kaʻina kalibration, ʻaʻohe palena kuʻuna i hoʻokumu ʻia

Ka pololei a me ka pololei

Product-axis mass accuracy 2.5 ppm; hoʻokaʻawale maʻamau precursor-axis 0.2 m/z

ʻIke hiki ke hana hou a me ka pololei waena

ʻO ke kūpaʻa

Hoʻoholo ʻia ma ka helu o nā ʻanuʻu modulation a me ka pae mua m/z

ʻO ka noʻonoʻo i ka mea kani a me ka hoʻololi ʻana i ke kaiapuni

Paʻa ʻikepili Polypeptides

ʻAʻole i ʻōlelo ʻia ma nā kumu Q-2DMS

ʻO nā ala hoʻopaʻa a me ka mālama ʻana i nā moʻolelo e like me nā manaʻo MHRA

Pono e hoʻonui ʻia nā mea komo ʻelua ma kēlā papa ʻaina. Ma ka quantitation, ʻO ka haʻawina Q-2DMS mua e ʻōlelo ana ʻaʻole i hōʻike wale ka nui o ka ikaika ma ka laina autocorrelation., no ka mea, ua hoʻopilikia pū ʻia lākou e ka maikaʻi o ka ʻāpana (Wright et al., 2026). He keakea pololei ia i ka hoʻohana ʻana i ke axis precursor ma ke ʻano he ana quantitative me ka hana ʻole. Ma ka pono o ka ʻikepili, ka MHRA GxP ʻikepili pololei alakaʻi e wehewehe i nā manaʻolana ALCOA a koi ʻia e hōʻoia ʻia nā ʻōnaehana analytical configurable no ka hoʻohana ʻana., me nā ala hoʻopaʻa hoʻopaʻa manawa kūpono a me ka mālama ʻana i ka moʻolelo kumu piha (MHRA, 2018). ʻAʻohe kumu e wehewehe pehea e mālama ʻia ai ka ʻikepili modulation raw Q-2DMS ma lalo o kēlā mau manaʻo.

ʻAʻole hoʻoholo ʻia ka palena o ka manawa kūʻai i nā hōʻike i hōʻoia ʻia. Hōʻike ka pepa Q-TOF i kahi kikoʻī 1024-pulse 2D (Wright et al., 2026), a ua ʻike ka pepa e hiki ke hoʻomaikaʻi ʻia ka hoʻonā ma ka hoʻonui ʻana i ka helu o nā ʻanuʻu modulation a i ʻole ka hōʻemi ʻana i ka pae mua m/z., akā, ma ka hana hoʻoholo e kuhikuhi ʻia e ka manawa kūʻai a me nā palena kūpono ʻē aʻe. A 15 i 17 Ua hōʻike ʻia ka helu minuke no kahi hoʻokolohua piha i ka nūhou, ʻaʻole naʻe i hōʻoia ʻia i ka laina i ka ʻaoʻao lalo, no laila e mālama e like me ka mea i hōʻike ʻia ma mua o ka hoʻopaʻa ʻia.

Nā ʻanuʻu aʻe

E kūkulu i ka loiloi e pili ana i ʻekolu nīnau ma mua o kahi koi hoʻokahi. Ka mua, ʻO ka papa haumia āu e hakakā maoli nei me ka hāʻule ʻana i loko o ka ʻāpana isobaric i ʻōlelo ʻia i ka precursor-fragment correlation address, a i ʻole ka ʻāpana isomeric kahi i loaʻa ʻole ai? ʻO ka 0.2 m/z palena hoʻokae a me ka 0.2 hōʻike ʻia ka ʻokoʻa maʻamau m/z ma ke aʻo kumu Q-2DMS ma Kemika Analytical hāʻawi iā ʻoe i ka palena (Wright et al., 2026).

Ka lua, he aha ke ala e hōʻike ai e hoʻokomo i kāu pūʻolo hōʻoia? I Q2(R2) papa inoa i nā ʻano hana e manaʻo ai ka mea loiloi, a ʻo ka hōʻike hōʻike Q-2DMS o kēia manawa e uhi i ka kikoʻī a me ka pololei nui i ka wā e haʻalele ana i ka laulā, palena quantitation, ʻO ka pololei a me ka ikaika e wehe (I Q2(R2), 2023).

E ana i ka manawa pōʻai holoʻokoʻa ma ka mea hana i manaʻo ʻia, me ka loaa ana ana, hoʻololi ʻana, ka hana ʻana a me nā ana hou ʻana. ʻAʻole hoʻokumu ka ʻatikala i kahi 17 mau minuke no kēlā me kēia laʻana no kahi peptide QC workflow.

Inā loaʻa iā ʻoe kahi kaʻina kahi i ola ai kahi ʻano co-eluting i ka hoʻokuʻu ʻana, ʻo ia ka hihia koʻikoʻi kūpono e kūkākūkā me kahi mea hoʻolako ma mua o ka hana ʻana i kahi kauoha, no ka mea, pili ka pane inā ʻokoʻa ka paʻa i ka m/z, i ka mokuʻāina mālama, a i ʻole ma stereochemistry wale nō.

Nīnau pinepine

Ua like anei ka Q-2DMS me 2D-LC?

ʻAʻole, a kaʻawale nā ​​ʻenehana ʻelua ma nā koʻi like ʻole. Hoʻopili ʻo Q-2DMS i nā waiwai mua a me ka ʻāpana m/z ma ke ʻano he ʻelua mau ana nui, no laila e hoʻopaʻa ʻia nā ʻāpana i ka precursor a lākou i hele mai ai me ka hoʻokaʻawale ʻole ʻana. 2ʻO D-LC kahi hana chromatographic: Hoʻoholo ia i nā analytes ma ka hana paʻa a ʻaʻole, iaia iho, e hoʻokuʻi i kahi ʻāpana i kona ion makua. Hōʻike ka lepili "2D" i ka nui o ka ʻikepili, ʻaʻole he hana like.

Hiki iā Q-2DMS ke hoʻololi i kaʻu ʻano hana LC-MS/MS?

ʻAʻohe kumu e hoʻonoho iā ia ma ke ʻano he pani pani, a ke hana nei ka hana i paʻi ʻia ma ke ʻano he kōkua. Ma ka haʻawina mua Q-2DMS, Hoʻohana mua ʻia kahi ʻano kikoʻī hoʻokahi-dimensional haʻahaʻa haʻahaʻa a i ʻole laser-off e hōʻike i nā precursors āpau i ka hoʻonā piha TOF a e hae i nā mea ʻaʻole e hoʻokaʻawale pololei i ka spectrum ʻelua-dimensional. (Wright et al., 2026). He ʻanuʻu kānana ia e hānai ana i ke ʻano i hoʻopaʻa ʻia, ʻaʻole kahi hoʻololi.

He aha ka ʻokoʻa m/z liʻiliʻi loa a Q-2DMS hiki ke hoʻokaʻawale?

Ma ka hōʻike hōʻike ʻehā-peptide i paʻi ʻia, nā mea mua 0.2 Ua hoʻokae ʻia ka m/z kaawale, aka, a 0.2 ʻO ka hoʻokaʻawale maʻamau m/z, ʻaʻole i kaʻawale loa nā puʻunaue ʻelua (Wright et al., 2026). E mālama 0.2 m/z e like me ka palena hoʻoholo i hoʻāʻo maoli ʻia e ka haʻawina, ʻaʻole i hōʻoia ʻia ka palena hana.

Pono ʻo Q-2DMS i kahi mea hana loea?

ʻAʻole. Ua holo ka hōʻikeʻike ma luna o kahi pae kūʻai kūʻai Q-TOF i hoʻokomo ʻia me kahi pahu hoʻonui, ʻo ia ka haʻalele pono ʻana mai ka 2DMS i hoʻokumu ʻia e ka ICR-cell a me kāna mau pono lako loea (Kulanui o Warwick, 2026).

Hiki iā Q-2DMS ke hoʻokaʻawale i nā isomer Leu/Ile a i ʻole Asp/isoAsp?

ʻAʻole ma ka axis precursor. Leucine a me ka isoleucine, e like me ka aspartate a me ka isoaspartate, kaʻana like i ka nuipa a me ka mokuʻāina hoʻoili, no laila ʻaʻole hiki i ka precursor m/z wale nō ke hoʻokaʻawale iā lākou; pono ka hoʻokae ʻana mai ka ʻano ʻāpana a i ʻole ka hoʻokaʻawale orthogonal. ʻO ke alakaʻi ʻEulopa e pili ana i nā peptides synthetic me ka manaʻo o ka mālama ʻana i nā diastereomers e koi i nā ala kikoʻī (ʻO ke alakaʻi a EMA i ka hoʻomohala ʻana a me ka hana ʻana i nā peptides synthetic).

Pehea ka lōʻihi o ka holo ʻana o ka Q-2DMS?

ʻAʻole i hoʻokumu ʻia kahi hana maʻamau no kēlā me kēia laʻana e nā hōʻike i hōʻuluʻulu ʻia ma aneʻi. E noi i nā hoʻonohonoho kūʻai maoli, manawa pōʻaiapuni piha a me ka hana ma ka laʻana i manaʻo ʻia ma mua o ka mālama ʻana i ka lōʻihi i hōʻike ʻia ma ke ʻano he kikoʻī i hōʻoia ʻia.

Ua hōʻoia ʻia ʻo Q-2DMS no ka hoʻokuʻu ʻana?

ʻAʻole. ʻO ka hana i paʻi ʻia he hōʻike hōʻikeʻike kumu, ʻaʻole he ala i hōʻoia ʻia, a ʻaʻohe kumu i hōʻike ʻia e like me ke kūpono no ka hoʻokuʻu pūʻulu. Pono e hōʻoia ʻia nā ʻano hana i hoʻohana ʻia no ka hoʻokuʻu ʻana no kāna kumu i manaʻo ʻia, ʻo ia hoʻi ka hoʻokumu ʻana i nā kikoʻī, pololei, pololei, ka laulā a me ka ikaika ma lalo o ka ICH Q2(R2) papa hana (I Q2(R2) alakaʻi no ka hōʻoia ʻana i ke kaʻina hana analytical). A hiki i ka loaʻa ʻana o kēlā pūʻolo no kahi peptide i hāʻawi ʻia, Aia ʻo Q-2DMS i ka hōʻailona, ʻaʻole ma kahi kikoʻī.

Ka hopena

ʻO ka hōʻuluʻulu ʻoiaʻiʻo o nā hōʻike ʻo ia ka Q-2DMS e hoʻololi i ka pale ʻenehana a me ka loaʻa ʻana o ka precursor-fragment correlation., ʻaʻole ke kumu physics. Ua kākau ʻia ka hōʻike mua benchtop ma kahi pāʻoihana Q-TOF me kahi pahu hoʻonui (Kulanui o Warwick, 2026), paʻi ʻia ka mīkini a me kona mau palena me nā helu kikoʻī (Wright et al., 2026), a ke kau nei ka hoʻopiʻi hoʻokō ma luna o ka hana hōʻoia-o-keʻena hoʻokolohua ma kahi hui ʻehā-peptide me ka loaʻa ʻole o ka hana hou kūʻokoʻa..

No ke alakai analytical, he haiki a hiki ke hoao ka rula hooholo. Inā he ʻano co-eluting kāu pilikia hou i ʻokoʻa i ka m/z a i ʻole ka mokuʻāina hoʻoili mai ka piko nui., pono ke kamaʻilio kūpono. Inā he stereochemistry kāu pilikia, quantitation e pili ana i ka palena kiko'ī, a i ʻole kahi ala hoʻokuʻu i hōʻoia ʻia, ʻaʻole hiki i nā hōʻike o kēia manawa, a ʻo nā ʻano hana orthogonal i koi ʻia e kāu framework pharmacopoeial e waiho i ka pane.


Mea hoʻopuka: MOL Changes. Hoʻohou 15 ʻOkakopa 2026. Hoʻopili kēia ʻatikala i nā kumu lehulehu i ʻōlelo ʻia a hāʻawi i kahi hoʻolālā hoʻolālā. ʻAʻole ia e hōʻike i kahi loiloi hoʻolako kūʻokoʻa a i ʻole kahi noiʻi hoʻokolohua MOL Changes kumu.

Hōʻike kālepa: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a loaʻa iā ia kahi hoihoi pāʻoihana i kēia kumuhana. Pono e hoʻopaʻa ʻia ka mana o ka papahana a me ka laulā analytical e kūʻē i ka hoʻohana i manaʻo ʻia a me kahi kikoʻī i kākau ʻia.

Zejun Peng

Zejun Peng

Luna ʻenehana Nui; ʻO ka mea akamai i ka peptide Synthesis Kaʻike kumu: ʻO ka peptide synthesis paʻakikī, nā hoʻololi ʻana o ka amino acid kūlohelohe, a me ke kūkulu ʻana i nā peptides cyclic a me nā peptides stapled.

moʻokalaleo:He ʻike nui ʻo Zejun Peng i ka kemika kūlohelohe a me ka synthesis peptide. Maikaʻi ʻo ia i ka hoʻohana ʻana o ka solid-phase peptide synthesis (SPSS) a me ka peptide synthesis wai (LPPS), a akamai loa i ka lanakila ʻana i nā "paʻakikī loa-e-synthesize sequences" (e like me nā peptides ultra-long-chain, nā kaʻina hydrophobic kiʻekiʻe, a me ka pelu ana i na mea paa disulfide lehulehu). Ma lalo o kāna alakaʻi, ua lanakila ka hui i nā bottlenecks ʻenehana i kekahi mau hoʻololi kūikawā (e like me ka N-methylation, PEGylation, a me ka lepili fluorescent), ka mālama ʻana i ka helu kūleʻa synthesis o luna 98%.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana